Otsuka can press ahead with ‘inconsistent’ defences in Abilify patent dispute

Allens 2019-02-27 8:38 pm By Miklos Bolza | Sydney

Please login to bookmark

Otsuka Pharmaceuticals and Bristol Myers-Squibb can retain their defences in an ongoing patent dispute over antipsychotic drug Abilify, after the Federal Court dismissed a strike out bid by the Commonwealth of Australia over the allegedly “inconsistent” pleadings.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au